US Patent Issued to CELGENE on Sept. 30 for "Engineering of an antibody for tumor-selective binding of CD47" (New Jersey Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,428,488, issued on Sept. 30, was assigned to CELGENE Corp. (Summit, N.J.).

"Engineering of an antibody for tumor-selective binding of CD47" was invented by Haralambos Hadjivassiliou (Summit, N.J.), Dan Zhu (Summit, N.J.), Jeonghoon Sun (Summit, N.J.), Sharmistha Acharya (Summit, N.J.), Jeffrey Johnson (Summit, N.J.), Henry Chan (Summit, N.J.), Kandasamy Hariharan (Summit, N.J.) and Ho Cho (Summit, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Antibodies are provided which comprise at least one Fab portion that binds CD47 and at least one Fab portion that binds the tumor associated antigen (TAA) CD20; wherein the Fab portion that binds CD47 exhibi...